Dimerix (ASX: DXB) is a clinical stage biopharmaceutical company with a scalable, proprietary platform technology called Receptor-HIT. Incorporated in 2004, Dimerix develops and commercialises patient preferred pharmaceutical products for global markets using our innovative receptor technology to identify and develop drugs in areas with an unmet need.
Dimerix has successfully used the Receptor-HIT technology to identify a novel treatment (DMX-200) that may transform the lives of patients with inflammatory diseases, such as kidney or lung diseases. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.
Dimerix comprises 2 distinct entities:
- Dimerix Limited (ASX:DXB)
- Dimerix Biosciences Pty Ltd (a wholly owned subsidiary of Dimerix Limited)
Dimerix adopts, as part of its core culture, values to which we all aspire aimed at driving the success of the business.
By adopting the company values, Dimerix employees will ensure that they are delivering the best possible outcomes to themselves, their fellow workmates, investors and business associates alike. It is expected that everyone will, every day, in every way, strive to meet these values as they go about their day to day activities.
Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.